SEOUL, Dec. 18 (Korea Bizwire) — South Korean drugmakers have begun the process to develop COVID-19 vaccines that are effective against the new omicron variant amid concerns that the highly transmissible strain may become a dominant one soon. As the omicron variant fuels fears around the world that the pandemic could rage during the winter [...]
SEOUL, Oct. 6 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Wednesday it has signed an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to extend capacity reservations for manufacturing COVID-19 vaccines by the end of 2022. The agreement was signed between SK Bioscience CEO Ahn Jae-yong and Richard Hatchett, CEO of [...]
SEOUL, Aug. 30 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Monday it has begun the phase three clinical trial of its COVID-19 vaccine candidate. GBP510, under development by SK Bioscience, a unit of the country’s No. 2 family-controlled conglomerate SK Group, was administered to the first participant. It comes nearly three weeks [...]
SEOUL, Aug. 10 (Korea Bizwire) – South Korean drugmaker SK Bioscience Co. has won an approval to conduct the phase three clinical trial of its COVID-19 vaccine candidate, drug authorities said Tuesday. The Ministry of Food and Drug Safety said GBP510, under development by SK Bioscience, a unit of the country’s No. 2 family-controlled conglomerate [...]
SEOUL, June 21 (Korea Bizwire) — SK Bioscience Co., a major South Korean pharmaceutical firm, said Monday it plans to invest 150 billion won (US$132 million) through 2024 to expand its production capacity of COVID-19 vaccines. SK Bioscience said the investment is meant to increase the production capacity of the production line based in Andong, [...]
SEOUL, May 23 (Korea Bizwire) – South Korea, touted as one of most successful countries in containing the new coronavirus pandemic without lockdowns, is gearing up for its next step to emerge as a global vaccine hub, with four COVID-19 vaccines already being or set to be produced here. The country’s vision to become a [...]
SEOUL, March 18 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. made a splash in its debut on the main bourse Thursday, closing at more than two times its initial public offering (IPO) price. Instantly after the opening bell, its stock price soared to the daily permissible ceiling of 169,000 won (US$149.43), up [...]
SEOUL, March 10 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. drew a record 64 trillion won (US$56 billion) in investor deposits during a two-day subscription period for its share sale, company officials said Wednesday. According to the officials, the deposits for SK Bioscience’s initial public offering (IPO) surpassed the two previous records [...]
SEOUL, March 9 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. on Tuesday kicked off a two-day public subscription for its initial public offering (IPO), seen as a high-profile share sale during the first half. SK Bioscience, a unit of South Korea’s No. 2 family-controlled conglomerate SK Group, has allowed individual investors to [...]
GAITHERSBURG, Md., Feb. 15 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement. In addition to the already existing manufacturing arrangement, SK Bioscience has obtained a license to manufacture and [...]